Evaxion A (EVAX) - News Archive

Breakthrough Results for EVX-01: Promising New Data from Phase 2 Study to be Presented at ASCO 2024 COPENHAGEN, Denmark, May 23, 2024 Evaxion Biotech A/S (NASDAQ: EVAX), a pioneering company in the development of AI-Imm...

Evaxion Biotech, a clinical-stage TechBio company specializing in AI-Immunology powered vaccines, has recently announced significant progress in its EVX-01 Phase 2 clinical trial. The trial focuses on evaluating the eff...

Promising Results for EVX-B1 Vaccine Antigens Against Staphylococcus aureus InfectionEvaxion Biotech, a clinical-stage TechBio company, has recently announced encouraging results in a series of large non-rodent animal i...

Evaxion Biotech A/S, a leading clinical-stage TechBio company specializing in AI-Immunology powered vaccines, recently held a Research & Development (R&D) Day at its Hørsholm facilities in Denmark. The event aimed to sh...

Asimily and IT2Trust Partner to Bring Best-in-Class IoT Security and Risk Management to the Nordic RegionSUNNYVALE, Calif. and BALLERUP, Denmark, Feb. 21, 2024 - Asimily, a leading Internet of Things (IoT) risk manageme...

In an exciting development in the field of vaccine research, Evaxion Biotech A/S has announced the successful completion of the initial phases of its vaccine collaboration with MSD (Merck & Co., Inc.). Leveraging the ex...

Evaxion Biotech Regains Compliance with Nasdaq Minimum Bid Price RequirementCOPENHAGEN, Denmark, Feb. 07, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in developing AI-Immunol...

With the rapid development of Artificial Intelligence (AI) technologies, the biotechnology and pharmaceutical industry is experiencing a transformative shift. Companies like NobleAI, OKX, and Evaxion Biotech are some of...

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology powered vaccines, has announced a breakthrough upgrade in its fight against cancer. The Copenhagen-based biotechnology f...

Evaxion Biotech A/S Completes ADS Ratio Change and Enhances Shareholder ValueCOPENHAGEN, Denmark, Jan. 22, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX), a leading clinical-stage TechBio company focusing on AI-Immunology po...

Share Buybacks in Spar Nord Bank Transactions: A Closer Look at Evaxion Biotech s Recent DevelopmentsIn recent press releases, both Spar Nord Bank and Evaxion Biotech have made significant announcements that have caught...

Evaxion Biotech A/S Announces ADS Ratio Change and Impact on Company SharesCOPENHAGEN, Denmark, Jan. 08, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology powered...

Private Placement Raises $5.3 Million for Evaxion Biotech A/S, with MSD Global Health Innovation Fund as Largest New ShareholderCopenhagen, Denmark - Evaxion Biotech A/S (NASDAQ: EVAX), a leading TechBio company special...

SINGAPORE, Nov. 29, 2023 - OKX, a prominent Web3 technology company, has recently announced significant updates regarding its integration with Equation, a decentralized perpetual contract platform built on Arbitrum. Thi...

Artificial Intelligence in Immunology: Evaxion s Precision Cancer Vaccine Concept Steals the Show at Annual MeetingCOPENHAGEN, Denmark, Nov. 28, 2023 - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio compan...